DCGI approves trials for Biocon, Quark new eye drug
The Dollar Business Bureau India’s leading Biopharmaceutical firm Biocon Ltd on Thursday said that the Drug Controller General of India (DCGI) has given approval to it and its partner Israel-based Quark Pharmaceuticals Inc to go on with the clinical trials on human subjects for their new drug candidate, 'QPI-1007', which is aimed to treat ocular neuroprotection. Both the companies also informed the randomisation of first patient in the country in the Phase II/III global study of the latest drug candidate, Biocon said in a statement. Randomisation is referred to as providing subjects to treatment groups to check selection and accidental bias. “Biocon and Quark Pharmaceuticals have got the approval from DCGI to go on with the study, the first ever ...
Biotech sector to be a US$ 100 billion industry by 2025
The Dollar Business Bureau The biotechnology sector is growing at the rate of 30 % annually and India is set to become home to the world’s third largest setup in the sector by 2025, said Harsh Vardhan, Union Minister for Science and Technology. “I see ten years down the road, a US $ 100-billion industry which will be the powerhouse of not only India’s pharmaceutical sector, but also be on a global scale,” said the minister, adding, “At this rate of growth, it looks likely to be bigger than the domestic pharmaceutical industry.” The minister was speaking at the inaugural session of the first phase of the Bio Innovation Centre (BIC) of the Rajiv Gandhi Centre for Biotechnology (RGCB), ...
